Business Wire

FLEXTRADE-SYSTEMS

Share
UBS Asset Management and J.P. Morgan Execute First Electronic Bilateral Trade via FlexTrade's FlexFI

FlexTrade Systems, a global leader in multi-asset execution and order management systems, today announced its first direct EU electronic execution between UBS Asset Management and J.P. Morgan on FlexTrade's Fixed Income EMS solution, FlexTRADER FI (FlexFI).

The bilateral electronic trade between UBS Asset Management (buy side) and J.P. Morgan was made possible by J.P. Morgan’s ability to provide its differentiated and high-quality electronic liquidity directly into UBS Asset Management's instance of FlexTrade's FlexFI solution. This type of integration enables UBS Asset Management to interact and source liquidity directly from their key liquidity providers, improving efficiency, enhancing trading-decision making, and positively impacting best execution.

Lynn Challenger, Global Head of Trading and Order Generation at UBS Asset Management, said: "Our bilateral connectivity to J.P. Morgan, using FlexTrade's fixed-income EMS, FlexFI, is the next big step in the electronification of our bond and credit trading activities. Working on this initiative with FlexTrade and J.P. Morgan, we have produced a highly sophisticated, transparent way of simplifying and streamlining our workflows and interacting with the sell-side."

Eddie Wen, Global Head of Digital Markets at J.P. Morgan, commented: "Over the past few years, J.P. Morgan has made significant strides in expanding the digital distribution of our liquidity to clients. J.P. Morgan’s ability to connect its liquidity directly into client workflows through EMS solutions like FlexTrade, delivers significant efficiency gains and cost savings to our clients. Further, this solution provides clients with greater choice in the ways they can execute with J.P.Morgan.“

Andy Mahoney, Managing Director, EMEA at FlexTrade, noted: "Working with UBS Asset Management and J.P. Morgan on this new initiative and the outcomes it can create illustrates how revolutionary an EMS can be for fixed income trading. Incorporating actionable sources of liquidity into the trading workflow seamlessly gives clients a unique view of the market. In addition, bringing manual, opaque processes into a machine-readable format offers a first step toward improving transparency and efficiency with technology. As a result of industry collaboration, we've delivered true innovation – at speed – in the fixed-income EMS space. This will be crucial to driving efficiency, ultimately benefiting the end investor.”

About FlexTrade Systems:

FlexTrade Systems is a global leader in high performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world's first broker-neutral, execution management trading system, which allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.

About UBS Asset Management:

UBS Asset Management is a large-scale asset manager with a presence in 23 markets. It offers investment capabilities and investment styles across all major traditional and alternative asset classes to institutions, wholesale intermediaries and wealth management clients around the world. It is a leading fund house in Europe, the largest mutual fund manager in Switzerland, the second largest fund of hedge funds manager and one of the largest real estate investment managers in the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005057/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release

SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye